Clinical evaluation of the effect on oral administration of Siddha classical drug VILVA ENNAI for the treatment of BRONCHIOLITIS.

Clinical evaluation of the effect on oral administration of VILVA ENNAI for the treatment of VALI KANAM.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/01/030216

Enrollment

Registered

2021-01-04

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J219- Acute bronchiolitis, unspecified

Interventions

Intervention1: VILVA ENNAI: Should be administered orally once a day at morning before the food for a period of 10 days Dose : 4 ml Control Intervention1: Not Applicable: Not Applicable

Eligibility

Inclusion criteria

Inclusion criteria: subjects with any of the following symptoms will be included in the study 1. Fever associated with Respiratory symptoms, Urinary tract symptoms and Gastrointestinal symptoms 2. Loss of appetite 3. Cough 4. Vomitting 5. Wheezing 6. Decreased urine output 7. Thirsty 8. Dryness of mouth 9. Constipation

Exclusion criteria

Exclusion criteria: 1. Children below 3 years and above 12 years 2. Fever due to malignancy, trauma, psychological factors 3. High grade fever 4. Cough with hemoptysis 5. Fever associated with other complications such as HIV, meningitis, Tuberculosis 6. Cardiac diseases 7. Chronic Renal diseases 8. Severe Dehydration

Design outcomes

Primary

Measure	Time frame
Decreases the body temperature, cough, vomitting, constipation and other clinical symptoms.Timepoint: 10 days	—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactDr K Shyamala MDs

Government Siddha Medical College and Hospital, Palayamkottai

shyamsujisathya@gmail.com9442277124

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026